Stifel Rates Apogee Therapeutics (APGE) hold, $135 Price Target
Stifel has downgraded Apogee Therapeutics to a 'Hold' rating with a target price of $135, a 1.85% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Stifel rated Apogee Therapeutics, Inc. ($APGE) "hold" with a $135 price target on June 24, 2026.
APGE
Apogee Therapeutics, Inc.
Key Points
- On June 24, 2026, Stifel analyst Akash Tewari lowered the rating on Apogee Therapeutics, Inc. to 'Hold' with a target price of $135. The stock is currently priced at $132.55.
- Stifel's $135 price target implies 1.85% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.55 share price.
- Stifel's downgrade follows a trend among analysts, as multiple firms have recently downgraded their ratings on Apogee, including Deutsche Bank and Citigroup.
- The company, focused on biologic therapies for inflammatory diseases, has a market cap of about $10.2 billion and is set to report earnings on November 9, 2026.
Get $APGE trade alerts by text
We text you when insiders, Congress or big funds trade $APGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures
Stifel Downgrades Apogee Therapeutics to Hold
Stifel has downgraded its rating on Apogee Therapeutics, Inc. (APGE) to 'Hold' with a target price of $135, as reported on June 24, 2026. The stock is currently trading at $132.55 on the NGM exchange.
Stifel vs. the S&P 500
Hypothetical returns from Stifel's disclosed trades, not real profit or advice. How we model this.
Why Stifel's Downgrade Matters
This downgrade changes Apogee's rating from a previous level of 'Buy' to 'Hold'. The new target price of $135 reflects a cautious outlook for the stock, which is just below its 52-week high of $135.09. Stifel's decision comes amid a broader trend of rating downgrades from other analysts.
How Other Analysts View Apogee
Several other firms have also adjusted their ratings on Apogee. On June 24, 2026, both TD Cowen and Guggenheim downgraded their ratings to 'Hold', while Deutsche Bank and Citigroup also made similar moves. Notably, Citigroup set its target price at $135, aligning with Stifel's new target. Truist Securities maintained its 'Hold' rating with a target price of $135, up from a prior target of $81, showing some confidence in the stock despite the downgrades.
Stock Performance Context
Apogee Therapeutics has seen a fluctuation in its stock price, trading near $132.55 as of June 24, 2026. This pricing positions the stock close to its 50-day moving average of $134.18, suggesting it has been stable in the short term. Investors may be watching closely, as the stock has a 52-week range between $35.39 and $135.09.
$APGE price target
Apogee Therapeutics, Inc. daily closes and this analyst's $135 target. Not advice.
Insider Buying and Selling at Apogee Therapeutics, Inc.
On June 22, 2026, Carl Dambkowski, the Chief Medical Officer, sold 26,400 shares at an average price of $132.60, totaling about $3.5 million. This transaction was part of a planned sale under Rule 10b5-1, which allows insiders to set up a predetermined schedule for selling shares.
What Apogee Therapeutics, Inc. Does
Apogee Therapeutics, Inc. develops therapies for immunological and inflammatory diseases. Its product pipeline includes treatments for conditions like asthma and atopic dermatitis. The downgrade by Stifel reflects a cautious stance on the company's near-term prospects as it navigates the biotech landscape.
What’s Next for Apogee
Investors will be looking ahead to Apogee's next earnings report on November 9, 2026. The recent downgrades from multiple analysts may indicate a cautious outlook for the company, which operates within a challenging biotechnology sector. As always, the latest Form 13F filings will provide insights into institutional positions, but they reflect past holdings and may not represent current investment strategies.
Related Filing Alerts
Source: Stifel's rating change on $APGE (Jun 24, 2026). Written by software, not financial advice. How we make alerts